epocrates

Trending Patient News: Week of November 3, 2025

November 7, 2025

Keeping you a step ahead is our priority. That's why we've gathered some of the top stories your patients might be seeing. Here are this week's highlights:

Trump's Tylenol comments ignite concerns about treating kids' fevers

(NBC News) — President Trump’s remarks discouraging Tylenol use in children and pregnant women have sparked confusion among parents. Pediatricians stress that acetaminophen remains safe when used correctly and warn against misinformation that could lead to harmful outcomes. Read more

Lilly's new weight loss drug shows promise in mid-stage trial

(NBC News) — Eli Lilly’s experimental obesity drug, eloralintide, helped patients lose up to 20% of their body weight in a mid-stage trial, prompting plans for late-stage testing. The drug targets the hormone amylin, offering a new approach beyond current GLP-1 therapies. Read more

To optimize health, sync your habits with your body clock. Here's how

(NPR) — Aligning daily routines like sleep, meals, and exercise with your body’s circadian rhythms can improve metabolic health and reduce disease risk. Experts recommend consistent schedules and time-restricted eating to keep internal clocks in sync. Read more

AI steps in to detect the world's deadliest infectious disease

(NPR) — In over 80 low- and middle-income countries, AI-powered x-ray screening is revolutionizing tuberculosis detection, enabling rapid diagnosis even in remote areas without radiologists. Advocates hail it as a game-changer in the fight against the world’s top infectious killer. Read more

Eli Lilly, Novo Nordisk negotiating deal with Trump administration on obesity drug prices

(ABC News) — The Trump administration is finalizing a deal with Eli Lilly and Novo Nordisk to lower prices on blockbuster obesity drugs like Wegovy and Zepbound, expanding access for Medicare patients and launching a new platform, TrumpRx, to offer discounted treatments directly to consumers. Read more

Content availability may vary; some sources may require payment or registration.

Any views, thoughts, and opinions expressed in these articles are solely that of the publication and/or author and do not reflect the views, opinions, policies, or position of epocrates and athenahealth.